Stocks Biogen Inc

  • Some of the names on the move ahead of the open.

  • Some of the names on the move ahead of the open.

  • Earnings season is shifting into high gear in the final week of January, with six Dow Jones components, and more than a fifth of the S&P 500 companies reporting.

  • Morgan Stanley has identified some 40 stocks that could be candidates for tender offers in the next 12 months using its new quantitative model.

  • unhappy_at_work_200.jpg

    At almost every turn, it seems an analyst has something negative to say.

  • prescription-drugs-2_200.jpg

    Jim Cramer’s researcher Nicole Urken reviews the potential biotech pipeline winners there were highlighted this week on Mad Money.

  • prescription-drugs-2_200.jpg

    “I want to circle back to a biotech story that you might have missed because it didn’t make a big splash,” says Jim Cramer.

  • CNBC Contributor Barbara Ryan is taking the pulse of health care stocks at this year's "Woodstock" of health care.

  • 3 Top Health Care Plays: Barbara Ryan

    Strong fundamentals and dominant market positions make three biotech/pharma names stand out, Barbara Ryan says.

  • This could be the most difficult earnings season in years, revealed "Mad Money" host Jim Cramer. Here’s what’s on his radar.

  • Stocks finished lower Thursday after the Fed meeting minutes revealed disagreement on how long the central bank should buy bonds and as investors took a pause following the previous session's sharp 'cliff' deal rally.

  • U.S. stock index futures held slight losses Thursday following the weekly jobless claims report and as investors booked profits following a sharp 2-percent rally in the previous session.

  • Some of the names on the move ahead of the open.

  • medicare.jpg

    TheStreet.com offers up 13 biotech predictions for 2013.

  • *Biogen hemophilia A drug effective in trial. BOSTON, Oct 31- Biogen Idec Inc said on Wednesday its experimental treatment for patients with hemophilia A, a disorder that inhibits coagulation of the blood, controlled bleeding with fewer treatments in a late-stage clinical trial. Glenn Pierce, Chief Medical Officer for Biogen's hemophilia program.

  • *3rd- quarter EPS $1.91 excluding items vs Street view $1.60. ``They put up a nice solid quarter,'' said RBC Capital Markets analyst Michael Yee. ``What's being appreciated in biotech is the consistent beat and raise by all four of the large cap biotechs this week and that's got the sector on the move.''.

  • *3rd- quarter EPS $1.91 excluding items vs Street view $1.60. Excluding one-time items, the company earned $1.91 per share, topping analysts' average expectations by 31 cents, according to Thomson Reuters I/B/E/S.

  • Earnings Flash: BIIB's Beats Estimates

    Biogen reports better-than-expected earnings, with CNBC's Seema Mody.

  • WESTON, Mass.-- Biotech drugmaker Biogen Idec Inc. said Thursday its profit grew more than 13 percent in the third quarter, led by sales of the company's multiple sclerosis treatment Avonex. The Massachusetts- based company said revenue from Avonex grew 8 percent to $736.2 million in the period.

  • Oct 25- Biogen Idec Inc on Thursday reported higher-than-expected third-quarter profit on increased sales of its drugs for multiple sclerosis and cancer, and the U.S. biotechnology company raised its full-year earnings forecast. Biogen posted a net profit of $398 million, or $1.67 per share, compared with a profit of $354 million, or $1.43 per share, a year ago.